Horama est une société de #biotech au stade clinique développant des traitements de #genetherapy ciblant des maladies rares de la rétine #santé" title="" class="btn" data-container="body" data-html="true" data-id="27911" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#b3d4fc" tabindex="0" data-original-title="Horama"> 209 5,026 5,026
Activities
Technologies
Entity types
Location
63B Av. Ledru Rollin, 75012 Paris, France
Paris
France
Employees
Scale: 2-10
Estimated: 40
SIREN
800830721Engaged corporates
9Added in Motherbase
5 years, 10 months agoCoave therapeutics
Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases.
We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.
Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
médecine, thérapie génique, ophtalmologie, Gene Therapy, Rare Ocular disease, and CNS disease
Coave therapeutics
Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases.
We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.
Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() Kurma Partners Startup accelerator & VC, Venture Capital and Private Equity Principals | Kurma Partners Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 10 Jan 2025 | | |
![]() Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 9 Jan 2025 | | |
![]() Alexion Pharmaceuticals, Inc. Pharmaceutical, Biotechnology, Biotechnology Research | Alexion Pharmaceuticals, Inc. Pharmaceutical, Biotechnology, Biotechnology Research | Other 19 Mar 2024 | | |
![]() Institut du Cerveau – Paris Brain Institute Startup accelerator & VC, Biotechnology Research | Institut du Cerveau – Paris Brain Institute Startup accelerator & VC, Biotechnology Research | Other 11 Mar 2024 | | |
![]() Atlanpole Biotherapies Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Atlanpole Biotherapies Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Not capitalistic Not partnership Event 6 Jun 2019 | | |
![]() Assurance Maladie Insurance, Government Administration | Assurance Maladie Insurance, Government Administration | Other 5 Jul 2017 | | |
![]() Paris Biotech Santé Startup accelerator & VC, Civic and Social Organizations | Paris Biotech Santé Startup accelerator & VC, Civic and Social Organizations | Other 19 Jun 2019 | | |
![]() Atlanpole Business Consulting and Services | Atlanpole Business Consulting and Services | Capitalistic Not partnership Not event 13 Nov 2017 | | |
![]() Omnes Startup accelerator & VC, Financial Services | Omnes Startup accelerator & VC, Financial Services | Capitalistic Not partnership Not event 15 Nov 2017 | |